GALT

Business Context and Reporting Period

Company: Galectin Therapeutics Inc. (GALT)
Reporting Period: Quarter ended September 30, 2025 (Q3 2025)
Business Overview: A clinical-stage biopharmaceutical company developing therapies for fibrotic diseases and cancer, primarily focusing on the lead candidate belapectin (GR-MD-02), a galectin-3 inhibitor. The company has no product revenue and operates at a loss.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The company reported no revenue for any period presented.

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses decreased significantly by 54% year-over-year for the nine-month period (from $30.0M to $16.7M). Research and Development (R&D) expenses dropped 51% to $12.4M, primarily due to the conclusion of the NAVIGATE clinical trial in Q1 2025.
• Debt and Liability Surge: Total current liabilities increased from $35.4M to $136.4M. This is driven by a new $10M line of credit draw and the reclassification of long-term convertible notes and lines of credit to current liabilities following maturity date extensions to September 2026.
• Derivative Liability Volatility: The fair value of derivative liabilities associated with convertible notes increased sharply from $0.4M to $3.7M, resulting in a non-cash loss of $3.3M for the nine months ended September 30, 2025.
• Cash Burn: Net cash used in operating activities improved (decreased) by $11.1M year-over-year to $17.8M, reflecting lower clinical trial spend.

Outlook, Risks, and Management Commentary

• Liquidity and Going Concern: Management states there is "substantial doubt" about the company's ability to continue as a going concern. However, with $11.5M in cash and a $10M available line of credit from Chairman Richard Uihlein, the company believes it can fund operations through June 30, 2026.
• Clinical Trial Results (NAVIGATE): Top-line results for the NAVIGATE trial (prevention of esophageal varices in NASH cirrhosis) were presented in December 2024. While the primary composite endpoint did not reach statistical significance in the Intent-to-Treat (ITT) population, the Per-Protocol Population (PPP) showed a 49.3% reduction in varices incidence (p<0.05). A U.S.-specific subset analysis showed a 68.1% reduction (p=0.02).
• Future Financing: The company intends to raise additional capital through debt or equity financings, collaborations, or partnerships to fund operations beyond mid-2026. There is no assurance such financing will be available on acceptable terms.
• Risk Factors: Key risks include the early stage of development, dependence on external capital, potential inability to demonstrate efficacy in future trials, and significant dilution from convertible debt and warrants.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $11.5M cash balance and the $10M related-party line of credit to sustain operations through the projected June 2026 date.
• Debt Maturity: Confirm the terms of the extended maturity dates (September 30, 2026) for the convertible notes and lines of credit, and the potential for forced conversion or repayment.
• Derivative Liability Impact: Assess the sensitivity of the $3.7M derivative liability to stock price fluctuations, as this creates significant non-cash volatility in net loss.
• NAVIGATE Trial Follow-up: Monitor for further data analysis from the 55 patients who completed 36 months of treatment and any strategic partnership discussions resulting from the U.S. subset data.
• Dilution Risk: Review the total potential dilution from outstanding warrants (~4M shares), options (~7.3M shares), and convertible debt/lines of credit (~37.5M shares).